相关实验视频

Updated: Jul 20, 2025

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

在炎症性肠道疾病中,疾病活动的生物标志物

Edyta Szymanska¹, Sylwia Szymanska¹, Maciej Dadalski¹

¹Department of Gastroenterology, Hepatology, Feeding Disorders, and Paediatrics, The Children's Memorial Health Institute, Warsaw, Poland.

Przeglad gastroenterologiczny

|August 4, 2023

概括

本综述探讨了炎症性肠道疾病 (IBD) 的新生物标志物,重点关注炎症和肠道透性. 它强调了需要先进的诊断工具,超越当前的标准,如便calprotectin.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
生物标志物发现发现

背景情况:

炎症性肠病 (IBD) 是一种具有复杂原因的慢性疾病,包括遗传学,免疫功能障碍,肠道微生物群失衡和环境触发因素.
诊断依赖于临床,内镜和组织病理学发现,但非侵入性生物标志物对于早期检测和监测至关重要.
便calprotectin是目前ECCO推的标准生物标志物,但对更具体的标志物仍在进行研究.

研究的目的:

审查新兴的生物标志物来检测IBD中的肠道炎症.
探索新的生物标记,表明IBD患者的肠道透性增加.
提供IBD生物标志物的当前景观和未来潜力的概述.

主要方法:

对最近关于IBD生物标志物研究的系统文献综述.
分析着重于炎症和肠道透性标记物的研究.
综合了有关新生物标志物的诊断和监测能力的发现.

主要成果:

几种新的生物标志物在区分IBD和功能性肠道疾病方面表现有前途.
新的标记物正在研究它们反映疾病活动和治疗反应的能力.
研究表明,在IBD管理中,除便calprotectin外还有生物标志物的潜力.

结论:

开发新的生物标志物对于改善IBD诊断和管理至关重要.
未来的研究应该专注于验证这些新型标记物的临床应用.
先进的生物标志物可以为IBD患者带来更个性化的治疗策略.

关键词:

生物标志物生物标志物埃拉芬 (Elafin) 是一个很长的时间.便中的calprotectin在便中产生.哈普托格洛宾 (Haptoglobin) 是一种蛋白质.炎症性肠病是一种炎症性肠病.这里是 zonulin zonulin 的位置.

更多相关视频

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...